Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates

Cancer Lett. 1996 Apr 19;102(1-2):31-7. doi: 10.1016/0304-3835(96)04151-1.

Abstract

The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Ehrlich Tumor / drug therapy*
  • Carcinoma, Ehrlich Tumor / metabolism
  • Cell Division / drug effects
  • Cell Survival / drug effects
  • Depsipeptides*
  • Drug Screening Assays, Antitumor
  • Enzyme Induction / drug effects
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / metabolism
  • Mice
  • Neoplasm Proteins / biosynthesis
  • Ornithine Decarboxylase / biosynthesis
  • Ornithine Decarboxylase / drug effects
  • Peptides, Cyclic / pharmacology*
  • Sulfur Radioisotopes
  • Urochordata / chemistry

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • Neoplasm Proteins
  • Peptides, Cyclic
  • Sulfur Radioisotopes
  • didemnins
  • Ornithine Decarboxylase
  • plitidepsin